Insmed reported $-91641000 in Net Income for its first fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Net Income Change
Acelrx Pharmaceuticals ACRX:US $ -8.96M 0.04M
Alexion Pharmaceuticals ALXN:US $ 636M 100.2M
Alimera Sciences ALIM:US $ -3.65M 2.67M
Arena Pharmaceuticals ARNA:US $ -118.42M 3.74M
Biomarin Pharmaceutical BMRN:US $ 12.94M 4.43M
Cytokinetics CYTK:US $ -47.1M 3.17M
Dynavax Technologies DVAX:US $ 0.89M 16.36M
Flexion Therapeutics FLXN:US $ -28556000 8.91M
Gilead Sciences GILD:US $ 1522M 207M
Heron Therapeutics HRTX:US $ -52.61M 9.67M
Insmed INSM:US $ -91641000 10.57M
Mirati Therapeutics MRTX:US $ -135.68M 34.59M
Novartis NVS:US $ 2896M 837M
Regeneron Pharmaceuticals REGN:US $ 1115.2M 34M
Sarepta Therapeutics SRPT:US $ -167.25M 22.07M
Seattle Genetics SGEN:US $ -84.58M 36.84M
Ultragenyx Pharmaceutical RARE:US $ -122.43M 13.71M
Vertex Pharmaceuticals VRTX:US $ 66.92M 586.21M